Clinical Trials Using Anakinra
Clinical trials are research studies that involve people. The clinical trials on this list are studying Anakinra. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and / or Refractory Multiple Myeloma
This is an open-label, multicenter, Phase 1 / 2 study to determine the safety and efficacy of JCARH125, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult subjects with relapsed and / or refractory multiple myeloma. The study will include a Phase 1 part to determine the recommended dose of JCARH125 in subjects with relapsed and / or refractory multiple myeloma, followed by a Phase 2 part to further evaluate the safety and efficacy of JCARH125 at the recommended dose. The safety and tolerability of JCARH125 in subjects who receive prophylactic treatment with anakinra will be evaluated in a separate Phase 1 cohort. The antitumor activity of JCARH125 in subjects who have been previously treated with BCMA-directed therapy will be evaluated in separate Phase 2a cohorts.
Location: 14 locations
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
This phase II trial studies how well anakinra works in preventing severe decreased brain function (neurotoxicity) and a dangerous condition called cytokine release syndrome (CRS) caused by CAR-T cells. T cells (a type of immune cells) are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added in the laboratory. The special receptor is called a chimeric antigen receptor (CAR) and this type of modified T cells are called CAR-T cells. Cytokines are proteins that control body’s inflammatory response. In CRS, a large amount of cytokines is released into the blood, which may cause changes in blood pressure and heartbeat, flu-like symptoms (nausea, fever, and chills), and / or affect the way lungs / liver / kidneys work. CAR-T cell therapy may also cause brain-related symptoms (neurotoxicity), such as dizziness, weakness, confusion, difficulty speaking, and / or possible paralysis, and / or coma. Anakinra works by blocking the protein IL-1 (interleukin-1) that is released into the blood during or shortly after CAR-T cell therapy and causes an inflammatory (swelling) reaction. Anakinra may prevent or reverse the severe side effects of CAR-T cell therapy.
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients with Recurrent or Refractory Large B-cell Lymphoma
This phase II trial studies how well anakinra works in preventing severe chimeric antigen receptor T-cell-related encephalopathy syndrome after chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma that has come back or has not responded to treatment. Immunosuppressive therapy, such as anakinra, is used to decrease the body’s immune response, which may prevent severe chimeric antigen receptor T-cell-related encephalopathy syndrome.
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients with B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
This phase II trial studies how well anakinra works in decreasing the occurrence of cytokine release syndrome (CRS) and damage to the nerves (neurotoxicity) in patients with B-cell lymphoma who are receiving CD-19 targeted chimeric antigen receptor T-cell (CAR-T) therapy. CAR-T cell therapy may be complicated by two potentially life-threatening side effects: CRS and neurotoxicity. Anakinra is a drug typically used to treat rheumatoid arthritis, but may also help in preventing CAR-T cell-related cytokine release syndrome and neurotoxicity.
Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington